TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial

BACKGROUND: The high recurrence rate of hepatocellular carcinoma (HCC) after surgery negatively affects the prognosis of patients. There is currently no widely accepted adjuvant therapy strategy for patients with HCC. A clinical study of effective adjuvant therapy is still needed. METHODS: In this p...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Weili, Peng, Wei, Qi, Xin, Qiu, Zhancheng, Wen, Tianfu, Li, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149831/
https://www.ncbi.nlm.nih.gov/pubmed/37139154
http://dx.doi.org/10.3389/fonc.2023.1138570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149831/
https://www.ncbi.nlm.nih.gov/pubmed/37139154
http://dx.doi.org/10.3389/fonc.2023.1138570

Ejemplares similares